Q1 Earnings Estimate for WVE Issued By Leerink Partnrs

Wave Life Sciences Ltd. (NASDAQ:WVE) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Wave Life Sciences in a research note issued to investors on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz expects that the company will earn ($0.28) per share for the quarter. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. Leerink Partnrs also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.13) EPS and FY2026 earnings at ($1.12) EPS.

Other research analysts have also issued research reports about the company. Jefferies Financial Group initiated coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective for the company. StockNews.com raised Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Wave Life Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Wave Life Sciences Stock Performance

WVE opened at $8.62 on Monday. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -7.77 and a beta of -1.04. The company has a fifty day moving average of $10.73 and a 200 day moving average of $11.73. Wave Life Sciences has a fifty-two week low of $4.25 and a fifty-two week high of $16.74.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%.

Institutional Trading of Wave Life Sciences

A number of large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in Wave Life Sciences during the 4th quarter worth $40,000. Quarry LP bought a new position in shares of Wave Life Sciences during the 4th quarter worth $62,000. KBC Group NV purchased a new position in shares of Wave Life Sciences during the fourth quarter valued at $67,000. Point72 DIFC Ltd bought a new stake in shares of Wave Life Sciences in the third quarter valued at about $98,000. Finally, Summit Investment Advisors Inc. lifted its stake in Wave Life Sciences by 31.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after acquiring an additional 2,308 shares during the period. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Insider Buying and Selling

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the transaction, the director now owns 16,115 shares of the company’s stock, valued at $157,443.55. This represents a 39.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in a transaction on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the sale, the chief executive officer now owns 338,351 shares of the company’s stock, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is owned by corporate insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.